Celcuity Inc. (CELC) Stock Price & How to Invest

Celcuity Inc. is a Minneapolis-based clinical-stage biotechnology company focused on targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a pan-PI3K/AKT/mTOR (PAM) inhibitor being developed for HR+/HER2- advanced breast cancer. Unlike single-node inhibitors such as alpelisib, capivasertib, and everolimus, gedatolisib is designed to block the whole pathway at once. In 2026 the pivotal Phase 3 VIKTORIA-1 trial hit its primary endpoint, with gedatolisib combination regimens roughly doubling progression-free survival versus alpelisib plus fulvestrant in the PIK3CA-mutant cohort, results presented at ASCO. The FDA granted Priority Review to the New Drug Application for the PIK3CA wild-type population with a PDUFA goal date of July 17, 2026.

The investment picture is the classic late-stage biotech setup: a large addressable market and strong trial data on one side, and pre-revenue economics with concentrated single-asset risk on the other. Celcuity has essentially no product revenue and funds heavy research spending from cash and a debt facility, so the stock trades on the probability and size of a gedatolisib launch rather than on trailing financials. The near-term FDA decision, the readout of additional cohorts and the VIKTORIA-2 first-line studies, and the company's ability to fund a commercial launch are the variables that matter most. Walnut is not an investment adviser, and a name like this carries outcomes that can swing sharply on single regulatory or clinical events.

Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Celcuity Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-revenue, clinical-stage)
• Market cap: ~$5B
• Share price (Jun 30, 2026): ~$105
• Q1 2026 net loss: ~$52.8M
• Q1 2026 R&D expense: ~$33.1M
• Cash & short-term investments: ~$205.7M

Because Celcuity has essentially no product sales, standard multiples like price-to-earnings or price-to-sales do not apply, and the market cap reflects the expected value of a gedatolisib approval and launch. Management has said current cash plus debt-facility drawdowns are expected to fund clinical activities through 2026, which places the funding runway alongside the launch timeline as a key watch item. Figures are approximate and as of the periods noted.

There are three common ways to get CELC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CELC sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CELC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

CELC is a single-asset, pre-revenue biotech whose story is the gedatolisib approval and launch, which makes it high-reward and high-risk in equal measure.

Whether CELC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CELC a buy?, and where the stock could go from here in the CELC stock forecast.

For income investors, whether CELC pays a dividend and how the payout looks is covered in does CELC pay a dividend?